The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI

British Journal of Haematology

Volumn 113, Issue 1, 2001, Pages 126-135

  Soligo, Davide ^a,d   Servida, Federica ^b   Delia, Domenico ^c   Fontanella, Enrico ^c   Lamorte, Giuseppe ^b   Caneva, Lorenza ^b   Fumiatti, Rossella ^b   Deliliers, Giorgio Lambertenghi ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Apoptosis; CD34 + haematopoietic progenitors; Cytotoxic agent; Myelogenous leukaemia; Proteasome inhibitor

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CISPLATIN; DNA FRAGMENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ULTRASTRUCTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; CISPLATIN; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENES, BCL-2; GENES, P53; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; LEUCINE; LEUKEMIA, MYELOID; MEMBRANE GLYCOPROTEINS; MICROSCOPY, ELECTRON; PACLITAXEL; PROTEASE INHIBITORS; TIME FACTORS; TRANS-ACTIVATORS;

EID: 0035000515     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02683.x     Document Type: Article

References (35)

1. Proteasome inhibitors: A novel class of potent and effective antitumor agents
2. Bcr-abl exerts its effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase 3
3. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukaemic lymphocytes
4. Mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway
5. Developmental changes of the 26 S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death
6. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations
7. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: A link between the apoptosome and the proteasome pathway
8. Activation of the cell death program by inhibition of proteasome function
9. BCR-ABL delays apoptosis upstream of procaspase 3 activation
10. 2/M-phase transition
11. A new flow cytometric method for discrimination of apoptotic cells and detection of their cell cycle specificity through staining of F-actin and DNA
12. Nuclear pores in the apoptotic cell
13. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines
14. DNA damageassociated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation
15. + leukaemic B cells: In vitro/in vivo correlations
16. Apoptosis and the dilemma of cancer chemotherapy
17. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
18. The process of ultrastructural changes from nuclei to apoptotic body
19. A combined assay of cell viability and in vitro cytotoxicity with a high water-soluble tetrazolium salt, neutral red and crystal violet
20. In vitro pharmacodynamics of 1-beta-arabinofuranosylcytosine: Synergy of antitumor activity with cis-diamminechloroplatinum
21. γ-radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo
22. Proteasome inhibitors induce mitochondriaindependent apoptosis in human glioma cells
23. BCL-2 gene family and the regulation of programmed cell death
24. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
25. Detailed analysis of cell cycle kinetics upon proteasome inhibition
26. The role of the ubiquitin-proteasome pathway in apoptosis
27. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
28. Role of the ubiquitin-proteasome pathway in regulating abundance of cyclin dependent kinase inhibitor p27
29. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukaemia cells
30. Dysregulation of apoptosis in cancer
31. In vitro and in vivo interactions between cisplatin and topotecan in ovarian carcinoma systems
32. Do all programmed cell death occur via apoptosis?
33. Simultaneous determination of cell surface antigens and apoptosis
34. Drug-induced apoptosis in B-cell chronic lymphocytic leukaemia: Relationship between p53 gene mutation and bcl/bax proteins in drug resistance
35. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies